CBAY实时信号 | 通过Getagraph.com最大化利润

购买 57092 min ago

@ $32.47

发出时间: 21 Mar 2024 @ 02:01

回报率: 0.03%

上一信号: Mar 20 - 02:47

上一信号: 出售

回报率: -0.03 %

Live Chart Being Loaded With Signals

Commentary (22 Mar 2024 @ 04:00):

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases...

Stats
今日成交量	0.00
平均成交量	4.16M
市值	3.73B
EPS	$0 ( 2024-03-21 )
下一个收益日期	( $-0.320 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-32.81
ATR14	$0.00700 (0.02%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-22	Loewy Caroline M	Sell	30 000	Employee Stock Option (right to buy)
2024-03-22	Loewy Caroline M	Sell	15 000	Employee Stock Option (right to buy)
2024-03-22	Loewy Caroline M	Sell	7 500	Employee Stock Option (right to buy)
2024-03-22	Loewy Caroline M	Sell	16 000	Employee Stock Option (right to buy)
2024-03-22	Loewy Caroline M	Sell	27 705	Employee Stock Option (right to buy)

INSIDER POWER
-97.48
Last 100 transactions
Buy: 127 470 \| Sell: 9 848 383

音量相关性

長: -0.17 (neutral)

短: -0.63 (weak negative)

Signal:(46.979) Neutral

Cymabay Therapeutics Inc 相关性

10 最正相关
XPDB	0.96
ROCL	0.956
HWEL	0.955
IXAQ	0.953
GDNR	0.953
ARTEU	0.952
VMGA	0.952
FNVT	0.952
AVAC	0.951
PWUP	0.951

10 最负相关
RMRM	-0.983
ASPS	-0.952
BFC	-0.945
EVLO	-0.943
CLFD	-0.942
CREG	-0.941
YJ	-0.941
STAB	-0.941
SYBT	-0.939
MMAT	-0.936

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Cymabay Therapeutics Inc 相关性 - 货币/商品

0.00
( neutral )

0.12
( neutral )

Cymabay Therapeutics Inc 财务报表

Annual	2023
营收:	$31.07M
毛利润:	$30.39M (97.81 %)
EPS:	$-0.990

FY	2023
营收:	$31.07M
毛利润:	$30.39M (97.81 %)
EPS:	$-0.990

FY	2022
营收:	$0
毛利润:	$-710 000 (0.00 %)
EPS:	$-1.350

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-1.304

Financial Reports:

No articles found.

Cymabay Therapeutics Inc

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.